Relative contribution of nonstructural protein 1 in dengue pathogenesis

Dengue is a major public health concern in the tropical and subtropical world, with no effective treatment. The controversial live attenuated virus vaccine Dengvaxia has boosted the pursuit of subunit vaccine approaches, and nonstructural protein 1 (NS1) has recently emerged as a promising candidate...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of experimental medicine Vol. 217; no. 9
Main Authors: Lee, Pei Xuan, Ting, Donald Heng Rong, Boey, Clement Peng Hee, Tan, Eunice Tze Xin, Chia, Janice Zuo Hui, Idris, Fakhriedzwan, Oo, Yukei, Ong, Li Ching, Chua, Yen Leong, Hapuarachchi, Chanditha, Ng, Lee Ching, Alonso, Sylvie
Format: Journal Article
Language:English
Published: United States Rockefeller University Press 07-09-2020
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dengue is a major public health concern in the tropical and subtropical world, with no effective treatment. The controversial live attenuated virus vaccine Dengvaxia has boosted the pursuit of subunit vaccine approaches, and nonstructural protein 1 (NS1) has recently emerged as a promising candidate. However, we found that NS1 immunization or passive transfer of NS1 antibodies failed to confer protection in symptomatic dengue mouse models using two non-mouse-adapted DENV2 strains that are highly virulent. Exogenous administration of purified NS1 also failed to worsen in vivo vascular leakage in sublethally infected mice. Neither method of NS1 immune neutralization changed the disease outcome of a chimeric strain expressing a vascular leak-potent NS1. Instead, virus chimerization involving the prME structural region indicated that these proteins play a critical role in driving in vivo fitness and virulence of the virus, through induction of key proinflammatory cytokines. This work highlights that the pathogenic role of NS1 is DENV strain dependent, which warrants reevaluation of NS1 as a universal dengue vaccine candidate.
Bibliography:Disclosures: The authors declare no competing interests exist.
ISSN:0022-1007
1540-9538
DOI:10.1084/jem.20191548